GYS2

glycogen synthase 2, the group of Glycosyl transferases group 1 domain containing

Basic information

Region (hg38): 12:21536107-21604847

Links

ENSG00000111713NCBI:2998OMIM:138571HGNC:4707Uniprot:P54840AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • glycogen storage disorder due to hepatic glycogen synthase deficiency (Strong), mode of inheritance: AR
  • glycogen storage disorder due to hepatic glycogen synthase deficiency (Strong), mode of inheritance: AR
  • glycogen storage disorder due to hepatic glycogen synthase deficiency (Strong), mode of inheritance: AR
  • glycogen storage disorder due to hepatic glycogen synthase deficiency (Supportive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Glycogen storage disease, type 0, liverARBiochemicalDietary management (eg, with frequent and overnight feeds) can be beneficialBiochemical; Gastrointestinal; Neurologic21032403; 4505568; 8831078; 9691087; 11483824; 12794686; 18341095; 20051115; 23426827

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GYS2 gene.

  • Glycogen storage disorder due to hepatic glycogen synthase deficiency (9 variants)
  • not provided (3 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GYS2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
8
clinvar
34
clinvar
5
clinvar
47
missense
5
clinvar
75
clinvar
11
clinvar
7
clinvar
98
nonsense
4
clinvar
3
clinvar
7
start loss
0
frameshift
4
clinvar
5
clinvar
2
clinvar
11
inframe indel
0
splice donor/acceptor (+/-2bp)
2
clinvar
6
clinvar
1
clinvar
9
splice region
6
2
8
non coding
16
clinvar
28
clinvar
40
clinvar
84
Total 10 19 102 73 52

Highest pathogenic variant AF is 0.0000657

Variants in GYS2

This is a list of pathogenic ClinVar variants found in the GYS2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
12-21536211-GTTTA-G Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jun 14, 2016)307976
12-21536270-G-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)307977
12-21536300-C-T Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)883250
12-21536322-AC-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jun 14, 2016)307978
12-21536386-AT-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jun 14, 2016)307979
12-21536409-C-T Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)883251
12-21536434-T-C Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 12, 2018)307980
12-21536486-A-G Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)884057
12-21536496-T-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 12, 2018)884058
12-21536516-T-TA Glycogen storage disorder due to hepatic glycogen synthase deficiency Likely benign (Jun 14, 2016)307981
12-21536546-T-C Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)884059
12-21536548-A-C Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)884060
12-21536595-G-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 12, 2018)307982
12-21536664-C-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Benign (Apr 27, 2017)884061
12-21536695-A-T Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 12, 2018)307983
12-21536717-A-G Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 12, 2018)307984
12-21536802-G-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Benign (Jun 29, 2018)307985
12-21536948-T-A not specified • Glycogen storage disorder due to hepatic glycogen synthase deficiency Benign (Aug 10, 2021)261460
12-21536966-T-C Likely benign (Oct 23, 2015)558809
12-21536994-G-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Likely benign (Oct 29, 2018)798247
12-21536998-C-A Glycogen storage disorder due to hepatic glycogen synthase deficiency Likely benign (Jan 15, 2024)720229
12-21536998-C-T Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Nov 19, 2023)2986212
12-21536999-G-A not specified • Glycogen storage disorder due to hepatic glycogen synthase deficiency Benign (Jan 22, 2024)137530
12-21537006-A-T Inborn genetic diseases Uncertain significance (Jan 16, 2024)3103385
12-21537011-A-G Glycogen storage disorder due to hepatic glycogen synthase deficiency Uncertain significance (Jan 13, 2018)307986

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GYS2protein_codingprotein_codingENST00000261195 1668659
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
9.79e-220.014612546312841257480.00113
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.1383743820.9800.00002034615
Missense in Polyphen169175.20.96462166
Synonymous-1.791661391.190.000007691329
Loss of Function0.8903642.20.8520.00000248456

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001550.00155
Ashkenazi Jewish0.0001040.0000992
East Asian0.0003260.000326
Finnish0.0001390.000139
European (Non-Finnish)0.001220.00121
Middle Eastern0.0003260.000326
South Asian0.003300.00327
Other0.0008160.000815

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan.;
Disease
DISEASE: Glycogen storage disease 0 (GSD0) [MIM:240600]: A metabolic disorder characterized by fasting hypoglycemia presenting in infancy or early childhood, high blood ketones and low alanine and lactate concentrations. Although feeding relieves symptoms, it often results in postprandial hyperglycemia and hyperlactatemia. {ECO:0000269|PubMed:9691087}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
PI3K-Akt signaling pathway - Homo sapiens (human);Insulin resistance - Homo sapiens (human);Starch and sucrose metabolism - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Glucagon signaling pathway - Homo sapiens (human);Insulin signaling pathway - Homo sapiens (human);Glycogen synthetase deficiency;Glycogenosis, Type III. Cori disease, Debrancher glycogenosis;Mucopolysaccharidosis VI. Sly syndrome;Sucrase-isomaltase deficiency;Glycogenosis, Type IV. Amylopectinosis, Anderson disease;Glycogenosis, Type VI. Hers disease;Starch and Sucrose Metabolism;AMP-activated Protein Kinase (AMPK) Signaling;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Insulin Signaling;Glycogen Metabolism;Metabolism of carbohydrates;Metabolism;insulin Mam;glycogen biosynthesis;Glycogen synthesis;insulin;Glycogen metabolism (Consensus)

Recessive Scores

pRec
0.573

Intolerance Scores

loftool
0.874
rvis_EVS
0.32
rvis_percentile_EVS
72.8

Haploinsufficiency Scores

pHI
0.132
hipred
Y
hipred_score
0.553
ghis
0.402

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.821

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gys2
Phenotype
cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype;

Gene ontology

Biological process
glycogen biosynthetic process;generation of precursor metabolites and energy;response to glucose
Cellular component
cytoplasm;cytosol;cytoskeleton;cell cortex;cortical actin cytoskeleton;ectoplasm
Molecular function
glycogen (starch) synthase activity;protein homodimerization activity;glycogen synthase activity, transferring glucose-1-phosphate